Which of the following is used to treat harmone responsive breast cancer
**Core Concept**
Estrogen receptor-positive (ER+) breast cancer is a type of hormone-responsive breast cancer that relies on estrogen for growth and proliferation. Treatment strategies often involve hormone therapy, which aims to reduce estrogen levels or block its effects on cancer cells.
**Why the Correct Answer is Right**
Tamoxifen is a selective estrogen receptor modulator (SERM) that acts as an estrogen antagonist in breast tissue, thereby inhibiting the growth of ER+ breast cancer cells. It binds to estrogen receptors on the cancer cells, blocking the action of estrogen and preventing its proliferative effects. Tamoxifen has been shown to reduce the risk of recurrence and improve survival in patients with ER+ breast cancer.
**Why Each Wrong Option is Incorrect**
**Option A:** Aromatase inhibitors (AIs) are another type of hormone therapy used to treat ER+ breast cancer, but they work by inhibiting the enzyme aromatase, which is involved in estrogen synthesis. While AIs are effective, they are not the correct answer in this context.
**Option B:** Trastuzumab is a monoclonal antibody used to treat HER2-positive breast cancer, not hormone-responsive breast cancer. It targets the HER2 protein on cancer cells, preventing them from growing and dividing.
**Option C:** Chemotherapy is a systemic treatment that uses drugs to kill cancer cells, but it is not specific to hormone-responsive breast cancer. While chemotherapy may be used in combination with hormone therapy, it is not the correct answer in this context.
**Clinical Pearl / High-Yield Fact**
Tamoxifen is often associated with an increased risk of endometrial cancer and thromboembolic events, which are important side effects to consider when prescribing this medication.
**Correct Answer:** A. Tamoxifen